PRVB - プロベンション・バイオ （Provention Bio Inc.） プロベンション・バイオPRVBのチャート
PRVBの企業情報
| symbol | PRVB |
|---|---|
| 会社名 | Provention Bio Inc （プロベンション・バイオ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Provention Bio Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D) Crohn’s disease ulcerative colitis lupus and other viral diseases. The Company’s principal product candidates include PRV-031 PRV-6527 PRV-300 PRV-3279 and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D. プロベンション・バイオは米国のバイオ医薬品企業。臨床段階で、免疫性疾患予防のための新規治療薬の開発・商業化に従事する。同社の医薬品候補「PRV-031」はテプリズマブおよびモノクロナ―ル抗体、「PRV-6527」は経口CSF-1R阻害剤、「PRV-3279」はル―プスの治療に使用される。本社所在地はニュ―ジャ―ジ―州オ―ルドウィック。 Provention Bio, Inc. is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay or prevention of clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. |
| 本社所在地 | P.O. Box 666 Oldwick NJ 08858 USA |
| 代表者氏名 | Ashleigh Palmer アシュレイ・パーマー |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 908-428-9136 |
| 設立年月日 | 42644 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.proventionbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/prvb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -20.31092 |
| 終値（lastsale） | 3.5 |
| 時価総額（marketcap） | 130730467 |
| 時価総額 | 時価総額（百万ドル） 125.22860 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 141.45560 |
| 当期純利益 | 当期純利益（百万ドル） -20.95360 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Provention Bio Inc revenues was not reported. Net loss applicable to common stockholders increased from $4.2M to $15.7M. Higher net loss reflects Research and development - Balancing val increase from $3.7M to $13.2M (expense) General and administrative - Balancing v increase from $227K to $1.5M (expense) Stock-based Compensation in R&D increase from $29K to $341K (expense). |
PRVBのテクニカル分析
PRVBのニュース
Provention Bio: Sanofi Acquires Provention Bio With A 273% Premium (NASDAQ:PRVB) 2023/03/26 07:52:57 Seeking Alpha
Sanofi proposed to acquire Provention Bio for $2.9B in cash at a 273% premium over the previous closing price. See why we maintain PRVB stock''s buy rating.
Why Provention Bio Stock Skyrocketed 256% This Week 2023/03/16 20:56:47 The Motley Fool
Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker.
Earnings Scheduled For March 16, 2023 2023/03/16 10:59:03 Benzinga
Companies Reporting Before The Bell • KVH Industries (NASDAQ: KVHI ) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million. • ImmunoPrecise Antibodies (NASDAQ: IPA ) is projected to report quarterly loss at $0.17 per share on revenue of $3.96 million. • Blue Apron Hldgs (NYSE: APRN ) is expected to report quarterly loss at $0.83 per share on revenue of $100.13 million. • Yiren Digital (NYSE: YRD ) is estimated to report earnings for its second quarter. • KE Holdings (NYSE: BEKE ) is likely to report quarterly earnings at $0.08 per share on revenue of $2.29 billion. • Hello Gr (NASDAQ: MOMO ) is projected to report quarterly earnings at $0.29 per share on revenue of $465.30 million. • Children''s Place (NASDAQ: PLCE ) is likely to report quarterly loss at $4.09 per share on revenue of $455.33 million. • Sidus Space (NASDAQ: SIDU ) is projected to report quarterly loss at $0.15 per share on revenue of $1.25 million. • WiSA Technologies (NASDAQ: WISA ) is expected to report quarterly loss at $17.
Provention Bio''s Earnings Outlook 2023/03/15 18:01:55 Benzinga
Provention Bio (NASDAQ: PRVB ) is set to give its latest quarterly earnings report on Thursday, 2023-03-16. Here''s what investors need to know before the announcement. Analysts estimate that Provention Bio will report an earnings per share (EPS) of $-0.46. Provention Bio bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Provention Bio Q4 2022 Earnings Preview 2023/03/15 17:54:03 Seeking Alpha
Provention Bio (PRVB) is scheduled to announce Q4 earnings results on Thursday, March 16th, before market open.The consensus EPS Estimate is -$0.43 and the consensus Revenue Estimate…
Provention Bio Inc. (NASDAQ:PRVB) Reduces -2.99% In A Week: What’s Taking The Stock Higher? 2023/01/28 15:00:00 Marketing Sentinel
In last trading session, Provention Bio Inc. (NASDAQ:PRVB) saw 0.63 million shares changing hands with its beta currently measuring 2.26. Company’s recent per share price level of $8.77 trading at $0.06 or 0.69% at ring of the bell on the day assigns it a market valuation of $751.59M. That closing price of PRVB’s stock is … Provention Bio Inc. (NASDAQ:PRVB) Reduces -2.99% In A Week: What’s Taking The Stock Higher? Read More »
Analysts Predict Provention Bio Inc. (NASDAQ: PRVB) To Loss -191.26% From Current Levels. 2023/01/17 13:30:00 Stocks Register
The trading price of Provention Bio Inc. (NASDAQ:PRVB) closed higher on Friday, January 13, closing at $10.30, 6.96% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $9.47 and $10.52. In examining the 52-week price action we see that the stock hit a 52-week … Analysts Predict Provention Bio Inc. (NASDAQ: PRVB) To Loss -191.26% From Current Levels. Read More »
Provention Bio Inc. (NASDAQ:PRVB) Shares Plunged -12.50% In A Week – But Can It Maintain Its Gains? 2023/01/07 15:00:00 Marketing Sentinel
In last trading session, Provention Bio Inc. (NASDAQ:PRVB) saw 1.15 million shares changing hands with its beta currently measuring 2.30. Company’s recent per share price level of $9.10 trading at $0.22 or 2.48% at ring of the bell on the day assigns it a market valuation of $780.69M. That closing price of PRVB’s stock is … Provention Bio Inc. (NASDAQ:PRVB) Shares Plunged -12.50% In A Week – But Can It Maintain Its Gains? Read More »
Provention Bio Inc. (PRVB) Shares Are Up 72.06% So Far This Year 2023/01/04 16:30:00 Marketing Sentinel
Provention Bio Inc. (NASDAQ:PRVB) has a beta value of 2.30 and has seen 1.53 million shares traded in the last trading session. The company, currently valued at $829.59M, closed the last trade at $9.67 per share which meant it lost -$0.9 on the day or -8.51% during that session. The PRVB stock price is -9.82% … Provention Bio Inc. (PRVB) Shares Are Up 72.06% So Far This Year Read More »
Provention Bio: Tzield Approved, But Neutral On Commercial Launch 2023/01/02 17:44:42 Seeking Alpha
Provention Bio''s Tzield approved by the FDA. Read more to see why we''re optimistic about PRVB stock but are on the sidelines for now.
Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022 2022/04/28 11:30:00 PR Newswire
RED BANK, N.J., April 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022, before…
Analysts Predict An Provention Bio Inc. (NASDAQ: PRVB) Spike? 2022/04/23 11:30:00 Stocks Register
Provention Bio Inc. (NASDAQ:PRVB) shares, rose in value on Friday, 04/22/22, with the stock price up by 0.53% to the previous day’s close as strong demand from buyers drove the stock to $5.64. Actively observing the price movement in the last trading, the stock closed the session at $5.61, falling within a range of $5.47 … Analysts Predict An Provention Bio Inc. (NASDAQ: PRVB) Spike? Read More »
Provention Bio''s Coxsackievirus Vaccine Candidate Elicits Durable Virus-Neutralizing Antibodies At Six Months 2022/03/28 19:27:06 Benzinga
Provention Bio Inc (NASDAQ: PRVB ) announced results from the final analysis of its first-in-human PROVENT study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate. Provention is developing PRV-101 for the prevention of acute CVB infection and its complications and the potential … Full story available on Benzinga.com